Drug intelligence / Profile preview

eOD-GT8 60mer

Development stage
Unknown
Lead developer
International AIDS Vaccine Initiative
Modality
Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

eOD-GT8 60mer is an experimental HIV-1 vaccine candidate designed using a germline-targeting strategy. Developed by the International AIDS Vaccine Initiative (IAVI) in collaboration with Scripps Research, it consists of an engineered outer domain (eOD) of the HIV-1 gp120 protein. This immunogen is specifically designed to have high affinity for the germline precursors of VRC01-class broadly neutralizing antibodies (bnAbs). The eOD is linked to a lumazine synthase (LumSyn) protein, which self-assembles into a 60-mer icosahedral nanoparticle to enhance immune recognition. In clinical trials, it is typically administered with the AS01B adjuvant. The primary goal of the vaccine is to prime rare B cell precursors that can eventually be matured into bnAbs through subsequent booster immunizations to prevent HIV infection.

Other names
eOD-GT8 60-mereOD-GT-8 60-mereOD-GT 8 60-mereOD-GT8eOD-GT-8eOD-GT 8engineered outer domain germline targeting version 8 60mer

Beyond the preview

Go deeper on eOD-GT8 60mer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on eOD-GT8 60mer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call